What is the debt of Merus this year?
Merus has a debt level of -204.25 USD this year.
Merus Debt 2024
Merus Debt
-204.25 USD
Ticker
MRUS
ISIN
NL0011606264
WKN
A2AKFX
In 2024, Merus's total debt was -204.25 USD, a 38.28% change from the -147.7 USD total debt recorded in the previous year.
Merus Aktienanalyse
What does Merus do?
Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Merus's Debt Structure
Merus's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Merus's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Merus’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Merus’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Merus stock
What was the debt of Merus compared to the previous year?
The debt of Merus has increased by 38.28% compared to the previous year increased.
What are the consequences of high debt for investors in Merus?
High debt can pose a risk for investors of Merus, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Merus?
Low debt means that Merus has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Merus affect the company?
An increase in debt of Merus can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Merus affect the company?
A reduction in debt of Merus can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Merus?
Some factors that can influence the debt of Merus include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Merus so important for investors?
The debts of Merus are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Merus take to change the debt?
To change the debt, Merus can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Merus pay?
Over the past 12 months, Merus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Merus is expected to pay a dividend of 0 USD.
What is the dividend yield of Merus?
The current dividend yield of Merus is .
When does Merus pay dividends?
Merus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Merus?
Merus paid dividends every year for the past 0 years.
What is the dividend of Merus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Merus located?
Merus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Merus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Merus from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Merus pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Merus in the year 2023?
In the year 2023, Merus distributed 0 USD as dividends.
In which currency does Merus pay out the dividend?
The dividends of Merus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Merus
Our stock analysis for Merus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
